Europe Heparin Market (Unfractionated Heparin, Low Molecular Weight Heparin & Ultra Low Molecular Weight Heparin) - Share, Growth, Trends and Forecast by 2022

Heparin is a sulfated glycosaminoglycan of mixed composition, released by the mast cells and blood basophils. It is used as the calcium or sodium salt in the prophylaxis and treatment of clotting disorders, blood transfusion, and blood sampling. Heparin augments the activity of anti-thrombin III, a natural compound that inhibits activated clotting factors.

Logo

Albany, NY -- (SBWire) -- 12/04/2015 --This report provides in-depth analysis of the heparin market in Europe. Stakeholders for this report include manufacturers of heparin products, crude heparin suppliers, heparin processing companies, and new players planning to enter the market.

The report provides qualitative and quantitative analysis of the heparin market in Europe. Qualitative analysis comprises market dynamics, trends, product overview, and country-level market information. Quantitative analysis includes market share held by companies in 2013, market size, and forecast for heparin product types across five major nations in Europe from 2012 to 2022. Market revenue is provided in terms of USD million from 2012 to 2022 along with the compound annual growth rate (CAGR %) from 2014 to 2022 for all the segments, considering 2013 as the base year. The executive summary of the report provides a snapshot of the heparin market in Europe with information on leading segments with respect to the market size, forecast value, market share of key players, growth rate (CAGR %) from 2014 to 2022, and growth factors.

Complete Report with TOC @ http://www.mrrse.com/europe-heparin-market

The market overview section comprises impact factors such as drivers, restraints, and opportunities for the heparin market in Europe. This factors would aid the stakeholders in establishing a strong foothold in the European heparin market. Furthermore, the market overview section comprises market attractiveness and value chain analysis. The market attractiveness analysis section provides a graphical view comparing the growth and market dynamics in different countries to identify the most attractive market for the period from 2014 to 2022. Value chain analysis offers detailed information on value addition activities in the manufacturing process of heparin-based pharmaceutical products.

Market share analysis is also provided in the market overview section of the report for the year 2013 in terms of value (%). Furthermore, the report analyzes different heparin product types such as unfractionated heparin, low molecular weight heparin, and ultra-low molecular weight heparin. The product type section provides market analysis for different types of heparin in Europe. This includes an overview of product types, indications for use, presence of any biosimilars, market drivers, issues, and regulations amended for its production and use. Prices of products vary based on product type and formulation. Formulations with different heparin concentrations and formulation type carry different prices across the countries in the European Union. Hence, the report provides average pricing analysis (based on the current prices) to offer an overview of prices of heparin-based pharmaceutical products in the EU.

Inquiry on this report @ http://www.mrrse.com/enquiry/1039

The report further provides market analysis for heparin in five major countries in the EU: the U.K., Germany, France, Italy, and Spain. Market analysis for different heparin types is provided for each of these countries from 2012 to 2022 along with the CAGR from 2014 to 2022. The market has been estimated for finished heparin formulation and has not considered its APIs. Major factors such as aging population and increasing prevalence of venous thromboembolism (VTE) that propel the market for heparin in Europe are elaborated in the country-level analysis. This section also covers certain regulations governing the manufacture and import of heparin in some countries.

Major players operating in the heparin market in Europe such as Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, Leo Pharma A/S, Pfizer, Inc., Sanofi S.A., and Syntex S.A. are profiled in this report. The report also provides important recommendations for these players and new entrants. These recommendations would enable the existing market players to expand their market share and help new companies establish their presence in the heparin market in Europe.

Request a Free Sample Copy of the Report @ http://www.mrrse.com/sample/1039

About MRRSE
MRRSE stands for Market Research Reports Search Engine, the largest online catalog of latest market research reports based on industries, companies, and countries. MRRSE sources thousands of industry reports, market statistics, and company profiles from trusted entities and makes them available at a click. Besides well-known private publishers, the reports featured on MRRSE typically come from national statistics agencies, investment agencies, leading media houses, trade unions, governments, and embassies.

Media Relations Contact

Mr. Nachiket Ghumare
Assistant Manager
MRRSE
518-618-1030
http://www.mrrse.com/europe-heparin-market

View this press release online at: http://rwire.com/646809